Table: Santen Pharm -9-MTH group results (IFRS)

SANTEN PHARMACEUTICAL

04/02/2020 06:00

Feb 4 (Reuters)- 
              Santen Pharmaceutical Co Ltd 
              CONSOLIDATED FINANCIAL HIGHLIGHTS 
     (in billions of yen unless specified) 
                   9 months ended      9 months ended       Year to 
                  Dec 31, 2019        Dec 31, 2018     Mar 31, 2020 
                     LATEST             YEAR-AGO          COMPANY   
                     RESULTS             RESULT          FORECAST   
  Sales              182.33              173.21           248.00    
                   (+5.3 pct)          (+2.7 pct)       (+6.0 pct)  
  Operating           28.94               33.66            34.50    
                   (-14.0 pct)         (+11.9 pct)      (-23.5 pct) 
  Pretax              28.96               32.41            34.30    
                   (-10.6 pct)         (+9.7 pct)       (-20.4 pct) 
  Net                 20.30               23.38                     
                   (-13.2 pct)         (-14.5 pct)                  
  EPS Basic         50.86 yen           57.44 yen        58.98 yen  
  EPS Diluted       50.71 yen           57.26 yen                   
  Ann Div                               26.00 yen        27.00 yen  
  -Q2 Div           13.00 yen           13.00 yen                   
  -Q4 Div                               13.00 yen        14.00 yen  
 
  NOTE - Santen Pharmaceutical Co Ltd. 
  (Figures are reported based on international accounting rules (IFRS).) 
  If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half 
  dividend and Q4 to the second-half dividend announced before a new corporate law in 
  2006 allowed companies to pay and report dividends on a quarterly basis.
  *Net - represents Net profit attributable to owners of the parent company. 
  To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4536.T